
Catalyst Biosciences Inc (NASDAQ:CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million.
A definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has allowed Vertex to acquire Catalyst's portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash.